SNHG1 and cancer: Moreover, high expression of SNHG1 could predict poor overall survival (HR = 2.32, 95% CI = 1.90–2.83), event-free survival (HR = 1.58, 95% CI = 1.06–2.35), recurrence-free survival (HR = 2.15, 95% CI = 1.23–3.77), progression-free survival (HR = 2.75, 95% CI = 1.70–4.46), and disease-free survival (HR = 1.93, 95% CI = 1.10–3.40) in patients with cancer.